Previous 10 | Next 10 |
CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb) PR Newswire Data follow the historic approval of the first gene therapy for hemophilia B, which reduces the rate of annu...
~ Historic approval represents the first gene therapy in Europe to treat hemophilia B and provides a new treatment option for patients that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy, and generates elevated and sustained factor IX levels ~ ...
Summary Hemgenix was approved by FDA. uniQure appears undervalued based on the value of milestones and royalties due to the company. During Q2, uniQure will release data on AMT-130, which is a binary event with an asymmetric risk reward. Summary Partner CSL obtaine...
Dutch biotech uniQure N.V. ( NASDAQ: QURE ) traded higher pre-market Tuesday in reaction to a licensing agreement with Apic Bio for APB-102, a gene therapy targeted at a rare form of neurodegenerative disorder, amyotrophic lateral sclerosis (ALS). The FDA has already cleared an invest...
~ License of APB-102 further strengthens uniQure’s pipeline of innovative gene therapies to treat neurological disorders and miRNA-based gene silencing programs ~ ~ APB-102 and uniQure’s c9orf72-ALS program have the potential to address most inherited forms of ALS ~ ...
LEXINGTON, Mass. and AMSTERDAM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that its partner, global biotechnology leader CSL (ASX: CSL), has received a p...
CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment PR Newswire Long-term data from the pivotal HOPE-B study show a on...
Summary Recent approval of Hemgenix therapy creates alpha opportunity. Market has responded swiftly and we see upside targets of $31.5 and then $49. The Hemophilia B treatment market is complex and in need of a remedial breakthrough, forming part of our buy thesis. Rate buy. ...
Summary FDA approval of uniQure N.V.'s Hemgenix for the treatment of adults with Hemophilia B achieved. There is potential to receive European approval of Hemgenix for the treatment of adults with Hemophilia B in 2023 on standard review timeline. Go-ahead given by DSMB to continue h...
~ IND Submission and Clinical Development Expected to Begin in 2023 ~ ~ Advancements in Manufacturing and Technology Platform Also Highlighted ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 29, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading ge...
News, Short Squeeze, Breakout and More Instantly...
~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~ ~ Immediate reduction in cash burn, projected to save $40 million annually ~ LEXINGTON, Mass. and AMSTERDAM, July 23, 2024 (GLOBE NEWSWIRE) -...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 2.5% to $131.38 on volume of 280,159,738 shares Maxeon Solar Technologies Ltd. (MAXN) fell 8.1% to $0.248 on volume of 217,585,873 shares Tesla Inc. (TSLA) rose 3.7% to $262.33 on volume of 159,323,492 s...